Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal

Although myasthenia gravis (MG) is recognized as an immunoglobulin G autoantibody‐mediated disease, the relationship between autoantibody levels and disease activity in MG is unclear. We sought to evaluate this landscape through systematically assessing the evidence, testing the impact of predefined variables on any relationship, and augmenting with expert opinion.

[1]  J. Maessen,et al.  The association between anti‐acetylcholine receptor antibody level and clinical improvement in myasthenia gravis , 2021, European journal of neurology.

[2]  F. Gao,et al.  No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients , 2021, Brain and behavior.

[3]  J. Leoni,et al.  C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis , 2020, Therapeutic advances in neurological disorders.

[4]  U. Kumari,et al.  Disease Severity Assessment and Short-Term Outcome in Patients with Myasthenia Gravis , 2020, Annals of Indian Academy of Neurology.

[5]  J. Howard,et al.  Clinical outcome measures following plasma exchange for MG exacerbation , 2019, Annals of clinical and translational neurology.

[6]  M. Inghilleri,et al.  Italian recommendations for the diagnosis and treatment of myasthenia gravis , 2019, Neurological Sciences.

[7]  D. Sanders,et al.  Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis , 2018, Neurology.

[8]  M. Farrugia,et al.  The Association of British Neurologists' myasthenia gravis guidelines , 2018, Annals of the New York Academy of Sciences.

[9]  N. Gilhus,et al.  Pathophysiology and immunological profile of myasthenia gravis and its subgroups. , 2017, Current opinion in immunology.

[10]  K. Claeys,et al.  Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis , 2017, Journal of Neurology.

[11]  J. Howard,et al.  Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis , 2016, Autoimmunity.

[12]  Nils Erik Gilhus,et al.  Myasthenia gravis: subgroup classification and therapeutic strategies , 2015, The Lancet Neurology.

[13]  H. Sasaki,et al.  Analysis of change in anti‐acetylcholine receptor antibody and effect on myasthenia gravis symptoms by adjusting tacrolimus dosage according to the blood concentration , 2015 .

[14]  A. Verbeek,et al.  The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. , 2015, Journal of neuromuscular diseases.

[15]  A. Vincent,et al.  Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population , 2014, Journal of the Neurological Sciences.

[16]  L. Mei,et al.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. , 2013, The Journal of clinical investigation.

[17]  H. Vrolijk,et al.  MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4 , 2013, Proceedings of the National Academy of Sciences.

[18]  M. Tsujihata,et al.  Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  V. Bril,et al.  The Quantitative Myasthenia Gravis Score: Comparison With Clinical, Electrophysiological, and Laboratory Markers , 2012, Journal of clinical neuromuscular disease.

[20]  Meier,et al.  68 Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms , 2012 .

[21]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[22]  J. Lindstrom,et al.  Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value , 2011, Neurology.

[23]  Huaizhou You,et al.  Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late‐onset Myasthenia Gravis , 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[24]  F. Ciaraffa,et al.  Anti-MuSK antibodies: Correlation with myasthenia gravis severity , 2006, Neurology.

[25]  B. Xiao,et al.  The significance of titin antibodies in myasthenia gravis , 2004, Journal of Neurology.

[26]  A. Vincent,et al.  Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies , 2001, Nature Medicine.

[27]  N. Black,et al.  The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.

[28]  A. Kokla,et al.  Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor , 1992, European journal of immunology.

[29]  A. Engel,et al.  The Membrane Attack Complex of Complement at the Endplate in Myasthenia Gravis a , 1987, Annals of the New York Academy of Sciences.

[30]  S. Self,et al.  Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. , 1982, The New England journal of medicine.

[31]  P. Limburg,et al.  RELATIONSHIP BETWEEN CHANGES IN ANTI‐ACETYLCHOLINE RECEPTOR ANTIBODY CONCENTRATION AND DISEASE SEVERITY IN MY ASTHENIA GRAVIS , 1981 .

[32]  J. Michelson,et al.  Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. , 1978, The New England journal of medicine.